J&J erhöht Forecast raised by strong Arzneimittelverkäufen from Investing.com

The health care company of Johnson & Johnson (NYSE:) with a strong profit and growth forecast for 2024, is following a quarter with robust sales in the onkology-sparte verzeichnete and the gesamtergebnisse supported by the analysts. In New Jersey, a purchase was made with a profit of US$10.15 for Aktie, which would receive a tax of 24 cents from the Medizintechnik repairer’s repair of the V-Wave. This current forecast is 10 cents above the forecast you can expect.

This forecast for Johnson & Johnson would be incorrect. The world that is now worth 89.4 billion and 89.8 billion US dollars for a year was a slight increase from the früherenspanspan of 89.2 billion to 89.6 billion US dollars. When the taxes in connection with mergers and the acquisition of the shares were estimated for an action of 9.86 to 9.96 US dollars, it was not the case that the forecast was of 10 to 10.10 US dollars for action .

I gave Johnson & Johnson’s Quartal team a profit of US$2.42 pro action. Due to a 9% analysis of Vorjahr’s figures, it is likely that LSEG has adopted an analyst consensus of US$2.21. The US dollar quarters are worth $22.5 million and its value is $22.16 million.

The world’s incurable medicine is awarded a rapid 19% in a quarter of the world, while the Krebs therapy Darzalex with 3 million US dollars receives a plus of 20.7% from last time. The US analysts paid US$2.92 billion for the quarter.

Trotz der Konkurrenz durch Biosimilars in meereren Marken konnte J&Js Psoriasis medications Stelara die erwartungen übertreffen. The value of the drugs fell 6.6% in the quarter to $2.68 billion, lagging analysts’ estimates of $2.43 billion. The Stelara would have been forecast to reach US$10 billion a year, with prices set to increase at more than US$7 million through 2025 as it entered the United States market.

Auch Carvykti, J&Js Krebszelltherapie, has paid a sum of $286 million worth $239 million. The therapy that offers the therapy can expand production at once, while the external activities are active, production is carried out in New Jersey and in Belgium.

J&J’s Medizintechnik-Sparte quarters are up 5.8% at a quick $7.9 billion, while analysts have gained $8.05 billion. Finanzvorstand Wolk is about the recovery in the Asia-Pazifik region, especially in China and Japan, the Leistung der Medizintechnik-Sparte in Quartal beeinträchtigten. During the month of July, J&J will be able to make changes to the Chinese market, which will ensure that changes can be made for the external components.

Reuters hat zu diesem Artikel beigetragen.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.